IL18 and metabolic dysfunction-associated steatohepatitis: We have previously shown that IL-18 administration not only remarkably improved dyslipidemia, NAFLD and NASH in Il18−/− mice, but it also inhibited body weight gain in Il18+/+ mice [10].